FDA expands marketing of 23andMe to include medication metabolism

The FDA expanded the marketing of the 23andMe Personal Genome Service Pharmacogenetic Reports test to provide information about 33 genetic variants that may be linked with a patient’s ability to metabolize some medications to help inform discussions with a health care provider, according to an agency press release.
“This test is a step forward in making information about genetic variants available directly to consumers and better inform their discussions with their health care providers. We know that consumers are increasingly interested in genetic information to help make

Full Story →